LifeVantage (LFVN) Completes Acquisition of LoveBiome

LifeVantage Corporation (NASDAQ:LFVN) is among the most profitable consumer defensive stocks to buy now. On Thursday, LifeVantage Corporation (NASDAQ:LFVN) announced the completion of its acquisition of LoveBiome, a direct sales company specializing in microbiome care and wellness solutions. The transaction encompasses LoveBiome’s core operating assets related to its microbiome health segment, as well as the retention of key personnel.

By integrating LoveBiome’s P84 product with the company’s top-tier technologies and compensation structure, this takeover enables LifeVantage Corporation (NASDAQ:LFVN) to expand its offerings into the gut health market while solidifying its presence in the United States, Taiwan, and Europe markets.

While LifeVantage Corporation (NASDAQ:LFVN) disappointed with the recent quarter’s results, the company has now positioned itself as a leader in the emerging microbiome health sector through the acquisition. As expressed by Steve Fife, President and CEO of LifeVantage Corporation (NASDAQ:LFVN),

“We are pleased to have closed the LoveBiome acquisition and look forward to working with Kelly Olsen and the LoveBiome team.”

LifeVantage Corporation (NASDAQ:LFVN), headquartered in Lehi, Utah, is a company that provides advanced nutrigenomic activators, dietary supplements, and skin and hair care products, among other products. With a commitment to transforming people’s lives, the company’s core offerings include Protandim, LifeVantage Omega+, and LifeVantage Daily Wellness.

While we acknowledge the potential of LFVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.